Yukon Wealth Management Inc. Has $698,000 Holdings in Johnson & Johnson $JNJ

Yukon Wealth Management Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,567 shares of the company’s stock after acquiring an additional 97 shares during the period. Yukon Wealth Management Inc.’s holdings in Johnson & Johnson were worth $698,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of JNJ. GFG Capital LLC acquired a new stake in Johnson & Johnson during the second quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research report on Monday, October 20th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $190.38 on Monday. The company’s 50 day simple moving average is $182.26 and its 200 day simple moving average is $166.37. The stock has a market capitalization of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.